Abstract C18: A phase I study of enavatuzumab (PDL192, ABT-361), a first-in-class human monoclonal antibody targeting TWEAK (tumor necrosis factor-like inducer of apoptosis) receptor, in patients (Pts) with advanced solid tumors.

Advanced Solid Tumors ◽

Antibody Targeting ◽

Phase I study of a fully human monoclonal antibody to the tumor necrosis factor-related apoptosis-inducing ligand death receptor 4 (TRAIL-R1) in subjects with advanced solid malignancies or non-Hodgkin's lymphoma (NHL)

10.1200/jco.2004.22.90140.2533 ◽

2004 ◽

Vol 22 (14_suppl) ◽

pp. 2533-2533 ◽

Cited By ~ 5

Author(s):

L. H. Le ◽

H. W. Hirte ◽

S. J. Hotte ◽

M. Maclean ◽

A. Iacobucci ◽

...

Keyword(s):

Monoclonal Antibody ◽

Tumor Necrosis Factor ◽

Phase I ◽

Phase I Study ◽

Tumor Necrosis ◽

Death Receptor ◽

Solid Malignancies ◽

Death Receptor 4 ◽

404 Phase I study of MEDI-575, a fully human monoclonal antibody targeting PDGFR-alpha in subjects with advanced solid tumors

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(10)72111-x ◽

2010 ◽

Vol 8 (7) ◽

pp. 128 ◽

Cited By ~ 1

Author(s):

R. Lechleider ◽

C. Becerra ◽

M. Liang ◽

R. Narwal ◽

L. Shi ◽

...

Keyword(s):

Monoclonal Antibody ◽

Phase I ◽

Solid Tumors ◽

Phase I Study ◽

Advanced Solid Tumors ◽

Antibody Targeting ◽

Pdgfr Alpha

Phase I Study of MK-4166, an Anti-Human Glucocorticoid-Induced Tumor Necrosis Factor Receptor Antibody, Alone or With Pembrolizumab in Advanced Solid Tumors

Clinical Cancer Research ◽

10.1158/1078-0432.ccr-20-2886 ◽

2020 ◽

pp. clincanres.2886.2020

Author(s):

Kyriakos P. Papadopoulos ◽

Karen A. Autio ◽

Talia Golan ◽

Konstantin Dobrenkov ◽

Elliot Chartash ◽

...

Keyword(s):

Tumor Necrosis Factor ◽

Phase I ◽

Solid Tumors ◽

Phase I Study ◽

Tumor Necrosis ◽

Tumor Necrosis Factor Receptor ◽

Advanced Solid Tumors ◽

Receptor Antibody ◽

Phase I Study of U3-1287, A Human Monoclonal Antibody Targeting Her3, in Japanese Patients with Advanced Solid Tumors

Annals of Oncology ◽

10.1016/s0923-7534(20)33026-x ◽

2012 ◽

Vol 23 ◽

pp. ix161-ix162

Author(s):

H. Wakui ◽

N. Yamamoto ◽

S. Nakamichi ◽

Y. Tamura ◽

H. Nokihara ◽

...

Keyword(s):

Monoclonal Antibody ◽

Phase I ◽

Solid Tumors ◽

Phase I Study ◽

Japanese Patients ◽

Advanced Solid Tumors ◽

Antibody Targeting

Phase I study of a fully human monoclonal antibody to the tumor necrosis factor-related apoptosis-inducing ligand death receptor 4 (TRAIL-R1) in subjects with advanced solid malignancies or non-Hodgkin's lymphoma (NHL)

10.1200/jco.2004.22.14_suppl.2533 ◽

2004 ◽

Vol 22 (14_suppl) ◽

pp. 2533-2533 ◽

Cited By ~ 10

Author(s):

L. H. Le ◽

H. W. Hirte ◽

S. J. Hotte ◽

M. Maclean ◽

A. Iacobucci ◽

...

Keyword(s):

Monoclonal Antibody ◽

Tumor Necrosis Factor ◽

Phase I ◽

Phase I Study ◽

Tumor Necrosis ◽

Death Receptor ◽

Solid Malignancies ◽

Death Receptor 4 ◽

First‐in‐human phase 1 study of MK‐1248, an anti–glucocorticoid‐induced tumor necrosis factor receptor agonist monoclonal antibody, as monotherapy or with pembrolizumab in patients with advanced solid tumors

Cancer ◽

10.1002/cncr.33133 ◽

2020 ◽

Vol 126 (22) ◽

pp. 4926-4935 ◽

Cited By ~ 1

Author(s):

Ravit Geva ◽

Mark Voskoboynik ◽

Konstantin Dobrenkov ◽

Kapil Mayawala ◽

Jennifer Gwo ◽

...

Keyword(s):

Monoclonal Antibody ◽

Tumor Necrosis Factor ◽

Solid Tumors ◽

Receptor Agonist ◽

Tumor Necrosis ◽

Phase 1 ◽

Tumor Necrosis Factor Receptor ◽

Advanced Solid Tumors ◽

Phase 1 Study ◽

A phase I study of CS-1008 (humanized monoclonal antibody targeting death receptor 5 or DR5), administered weekly to patients with advanced solid tumors or lymphomas

10.1200/jco.2008.26.15_suppl.3537 ◽

2008 ◽

Vol 26 (15_suppl) ◽

pp. 3537-3537 ◽

Cited By ~ 18

Author(s):

M. N. Saleh ◽

I. Percent ◽

T. E. Wood ◽

J. Posey ◽

J. Shah ◽

...

Keyword(s):

Monoclonal Antibody ◽

Phase I ◽

Solid Tumors ◽

Phase I Study ◽

Death Receptor ◽

Advanced Solid Tumors ◽

Death Receptor 5 ◽

Humanized Monoclonal Antibody ◽

Antibody Targeting

A first-in-human phase I study to evaluate the fully human monoclonal antibody MNRP1685A (anti-NRP1) administered intravenously every three weeks in patients with advanced solid tumors.

10.1200/jco.2010.28.15_suppl.3014 ◽

2010 ◽

Vol 28 (15_suppl) ◽

pp. 3014-3014 ◽

Cited By ~ 4

Author(s):

C. D. Weekes ◽

P. Hegde ◽

Y. Xin ◽

R. Yu ◽

H. Xiang ◽

...

Keyword(s):

Monoclonal Antibody ◽

Phase I ◽

Solid Tumors ◽

Phase I Study ◽

Advanced Solid Tumors

Phase I Study of Enavatuzumab, a First-in-Class Humanized Monoclonal Antibody Targeting the TWEAK Receptor, in Patients with Advanced Solid Tumors

Molecular Cancer Therapeutics ◽

10.1158/1535-7163.mct-17-0330 ◽

2017 ◽

Vol 17 (1) ◽

pp. 215-221 ◽

Cited By ~ 7

Author(s):

Elaine T. Lam ◽

S. Gail Eckhardt ◽

Wells Messersmith ◽

Antonio Jimeno ◽

Cindy L. O'Bryant ◽

...

Keyword(s):

Monoclonal Antibody ◽

Phase I ◽

Solid Tumors ◽

Phase I Study ◽

Advanced Solid Tumors ◽

Humanized Monoclonal Antibody ◽

Antibody Targeting

First-in-human phase 1 study of MK-1248, an anti-human glucocorticoid-induced tumor necrosis factor receptor (GITR) monoclonal antibody, as monotherapy or in combination with pembrolizumab in patients with advanced solid tumors.

10.1200/jco.2018.36.15_suppl.3029 ◽

2018 ◽

Vol 36 (15_suppl) ◽

pp. 3029-3029 ◽

Cited By ~ 6

Author(s):

Ravit Geva ◽

Mark Voskoboynik ◽

Amy M Beebe ◽

Jennifer Gwo ◽

Konstantin Dobrenkov ◽

...

Keyword(s):

Monoclonal Antibody ◽

Tumor Necrosis Factor ◽

Solid Tumors ◽

Tumor Necrosis ◽

Phase 1 ◽

Tumor Necrosis Factor Receptor ◽

Advanced Solid Tumors ◽

Phase 1 Study ◽